Non-invasive detection of 2-hydroxyglutarate in IDH-mutated gliomas using two-dimensional localized correlation spectroscopy (2D L-COSY) at 7 Tesla

The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary

(2016) David N. Louis et al.   ACTA NEUROPATHOLOGICA

In vivo detection of 2-hydroxyglutarate in brain tumors by optimized point-resolved spectroscopy (PRESS) at 7T

(2016) Sandeep K. Ganji et al.   MAGNETIC RESONANCE IN MEDICINE

Noninvasive Quantification of 2-Hydroxyglutarate in Human Gliomas with IDH1 and IDH2 Mutations

(2015) U. E. Emir et al.   CANCER RESEARCH

Why Glioma Patients Seize

(2014) Taylor B. Nelp et al.   NEUROSURGERY

Implementation of two-dimensional L-COSY at 7 tesla: An investigation of reproducibility in human brain

(2013) Gaurav Verma et al.   JOURNAL OF MAGNETIC RESONANCE IMAGING

Molecular pathogenesis of IDH mutations in gliomas

(2012) Koichi Ichimura   Brain Tumor Pathology

Detection of “oncometabolite” 2-hydroxyglutarate by magnetic resonance analysis as a biomarker of IDH1/2 mutations in glioma

(2012) Juliya Kalinina et al.   JOURNAL OF MOLECULAR MEDICINE-JMM

Immunohistochemical detection of IDH1 mutation, p53, and internexin as prognostic factors of glial tumors

(2012) Shingo Takano et al.   JOURNAL OF NEURO-ONCOLOGY

2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas

(2012) Changho Choi et al.   NATURE MEDICINE

Detection of 2-Hydroxyglutarate in IDH-Mutated Glioma Patients by In Vivo Spectral-Editing and 2D Correlation Magnetic Resonance Spectroscopy

(2012) O. C. Andronesi et al.   Science Translational Medicine

Magnetic Resonance of 2-Hydroxyglutarate in IDH1-Mutated Low-Grade Gliomas

(2012) A. Elkhaled et al.   Science Translational Medicine

Discovery of the First Potent Inhibitors of Mutant IDH1 That Lower Tumor 2-HG in Vivo

(2012) Janeta Popovici-Muller et al.   ACS Medicinal Chemistry Letters

Detection of IDH1 mutation in human gliomas: comparison of immunohistochemistry and sequencing

(2011) Shingo Takano et al.   Brain Tumor Pathology

Predictive and prognostic factors for gliomas

(2011) François Ducray et al.   Expert Review of Anticancer Therapy

Glutamine: pleiotropic roles in tumor growth and stress resistance

(2011) Naval P. Shanware et al.   JOURNAL OF MOLECULAR MEDICINE-JMM

Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy

(2011) Whitney B. Pope et al.   JOURNAL OF NEURO-ONCOLOGY

2-Hydroxyglutarate Production, but Not Dominant Negative Function, Is Conferred by Glioma-Derived NADP+-Dependent Isocitrate Dehydrogenase Mutations

(2011) Genglin Jin et al.   PLoS One

Use of in Vivo Two-dimensional MR Spectroscopy to Compare the Biochemistry of the Human Brain to That of Glioblastoma

(2011) Saadallah Ramadan et al.   RADIOLOGY

Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas

(2010) Christian Hartmann et al.   ACTA NEUROPATHOLOGICA

Oncometabolite? IDH1 Discoveries Raise Possibility of New Metabolism Targets in Brain Cancers and Leukemia

(2010) K. Garber   JNCI-Journal of the National Cancer Institute

IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas

(2010) C. Houillier et al.   NEUROLOGY

Mutant IDH1-specific immunohistochemistry distinguishes diffuse astrocytoma from astrocytosis

(2009) Sandra Camelo-Piragua et al.   ACTA NEUROPATHOLOGICA

Isocitrate Dehydrogenase 1 Codon 132 Mutation Is an Important Prognostic Biomarker in Gliomas

(2009) Marc Sanson et al.   JOURNAL OF CLINICAL ONCOLOGY

Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

(2009) Lenny Dang et al.   NATURE

IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas

(2009) Koichi Ichimura et al.   NEURO-ONCOLOGY

IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide

(2009) H. J. Dubbink et al.   NEUROLOGY

IDH1andIDH2Mutations in Gliomas

(2009) Hai Yan et al.   NEW ENGLAND JOURNAL OF MEDICINE